| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7ad58d3c0b071069a8ee0cb8c8ba2e8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4706 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2020-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7728ef771430e877497a884f58fef068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6317a4a0d744e064de8a321b0af15acd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e92578c41f349f95a9dc803b3ab6ba3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe52d4a73444914fba4591780a37523a |
| publicationDate |
2021-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021110731-A1 |
| titleOfInvention |
Method for determining the response of prostate cancer patients to treatment with androgen receptor antagonists based on gene expression changes or super-enhancer protein-binding profiles |
| abstract |
The present invention refers to a method and kit for determining the impact of AR antagonists in prostate cancer patients by determining changes in expression levels of selected genes and/or the binding of MED1 and/or AR and/or FOXA1 and/or histone H3 lysine acetylation to SE regions. This can be measured in vitro in a sample of body fluid or tumor tissue obtained from prostate cancer patients. |
| priorityDate |
2019-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |